Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee; Amendment of Notice, 20327-20328 [2013-07843]
Download as PDF
Federal Register / Vol. 78, No. 65 / Thursday, April 4, 2013 / Notices
addressed adhesive labels to assist that
office in processing your request, or fax
your request to 240–632–6861. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the draft CPG.
Submit electronic comments on the
draft CPG to https://www.regulations.gov.
Submit written comments to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
FOR FURTHER INFORMATION CONTACT:
Mischelle B. Ledet, Center for Food
Safety and Applied Nutrition (HFS–
615), Food and Drug Administration,
5100 Paint Branch Pkwy., College
Park, MD 20740, 240–205–1165; or
Kim R. Young, Center for Veterinary
Medicine (HFV–230), Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240–276–9200.
SUPPLEMENTARY INFORMATION:
wreier-aviles on DSK5TPTVN1PROD with NOTICES
I. Background
FDA is announcing the availability of
a draft CPG entitled ‘‘Compliance Policy
Guide Sec. 100.250 Food Facility
Registration—Human and Animal
Food.’’ The draft CPG is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft CPG, when finalized, will
replace ‘‘Compliance Policy Guide Sec.
110.300 Registration of Food Facilities
Under the Public Health Security and
Bioterrorism Preparedness and
Response Act of 2002.’’
Section 415 of the FD&C Act (21
U.S.C. 350d) requires owners, operators,
or agents in charge of domestic and
foreign facilities that manufacture,
process, pack, or hold food for human
or animal consumption in the United
States to register their facilities with
FDA, unless an exception applies (see
21 CFR 1.226 and 1.227). The FDA Food
Safety Modernization Act (FSMA) (Pub.
L. 111–353), enacted on January 4, 2011,
amended section 415 of the FD&C Act
in relevant part to require registrants for
food facilities to submit additional
registration information to FDA, and to
require facilities required to register
with FDA to renew such registrations
biennially. FSMA also amended section
415 of the FD&C Act to provide FDA
with authority to suspend the
registration of a food facility in certain
circumstances. Specifically, if FDA
determines that food manufactured,
processed, packed, received, or held by
a registered facility has a reasonable
probability of causing serious adverse
health consequences or death to humans
or animals, FDA may by order suspend
the registration of a facility that: (1)
Created, caused, or was otherwise
VerDate Mar<15>2010
14:48 Apr 03, 2013
Jkt 229001
responsible for such reasonable
probability; or (2) knew of, or had
reason to know of, such reasonable
probability; and packed, received, or
held such food.
The draft CPG is intended to provide
guidance for FDA staff regarding
enforcement of the food facility
registration provisions of section 415 of
the FD&C Act, including the
requirement that certain food facilities
register with FDA, the requirement that
registered facilities biennially renew
their registrations with FDA, and FDA’s
authority to suspend a food facility’s
registration. The draft CPG also contains
information that may be useful for the
regulated industry and to the public.
The draft CPG, when finalized, will
represent the Agency’s current thinking
on food facility registration
requirements of section 415 of the FD&C
Act. It does not create or confer any
rights for or on any person and does not
operate to bind FDA or the public. An
alternate approach may be used if such
approach satisfies the requirements of
the applicable statutes and regulations.
II. Paperwork Reduction Act of 1995
This draft guidance refers to
previously approved collections of
information found in FDA regulations
and section 415 of the FD&C Act. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
21 CFR 1.230 through 1.235 and section
415 of the FD&C Act have been
approved under OMB Control No. 0910–
0502.
III. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
IV. Electronic Access
Persons with access to the Internet
may obtain the draft CPG from FDA’s
Office of Regulatory Affairs history
page. It may be accessed at https://
www.fda.gov/ICECI/
ComplianceManuals/
CompliancePolicyGuidanceManual/
default.htm. Guidance documents are
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
20327
also available at https://
www.regulations.gov.
Dated: March 22, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–07809 Filed 4–3–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0001]
Joint Meeting of the Advisory
Committee for Reproductive Health
Drugs and the Drug Safety and Risk
Management Advisory Committee;
Amendment of Notice
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug Administration
(FDA) is announcing an amendment to
the notice of the joint meeting of the
Advisory Committee for Reproductive
Health Drugs and the Drug Safety and
Risk Management Advisory Committee.
This meeting was announced in the
Federal Register of March 14, 2013 (78
FR 16271–16272). The amendment is
being made to reflect a change in the
Agenda portion of the document. There
are no other changes.
FOR FURTHER INFORMATION CONTACT:
Kalyani Bhatt, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31 rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–9001, FAX: 301–847–8533,
ACRHD@fda.hhs.gov, or use the FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington DC area), and follow the
prompts to the desired center or product
area. Please call the Information Line for
up-to-date information on this meeting.
SUPPLEMENTARY INFORMATION: In the
Federal Register of March 14, 2013,
FDA announced that a joint meeting of
the Advisory Committee for
Reproductive Health Drugs and the Drug
Safety and Risk Management Advisory
Committee would be held on April 18,
2013. On page 16272, in the first
column, the Agenda portion of the
document is changed to read as follows:
Agenda: The committee will discuss
the efficacy and safety of new drug
application (NDA) 22219, AVEED
(testosterone undecanoate)
intramuscular injection, submitted by
Endo Pharmaceutical Solutions, Inc., for
the proposed indication of replacement
E:\FR\FM\04APN1.SGM
04APN1
20328
Federal Register / Vol. 78, No. 65 / Thursday, April 4, 2013 / Notices
therapy in adult males for conditions
associated with a deficiency or absence
of testosterone. The safety discussion
will focus on postmarketing reports of
oil microembolism in the lungs and
potential anaphylactic reactions. In
addition to AVEED, other approved
testosterone injectable products will be
referenced, especially in regard to oil
microembolism and potential
anaphylactic reactions reported for
those products.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to the advisory committees.
Dated: March 27, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
Dated: March 27, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2013–07842 Filed 4–3–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0001]
Peripheral and Central Nervous
System Drugs Advisory Committee;
Notice of Meeting
AGENCY:
ACTION:
[FR Doc. 2013–07843 Filed 4–3–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0001]
Orthopaedic and Rehabilitation
Devices Panel of the Medical Devices
Advisory Committee: Notice of
Postponement of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is postponing the
meeting of the Orthopaedic and
Rehabilitation Devices Panel of the
Medical Devices Advisory Committee
scheduled for April 5, 2013. The
meeting was announced in the Federal
Register of November 29, 2012 (77 FR
71195). The meeting is postponed
because key participants were
unavailable due to unforeseen
scheduling conflicts. In the meantime,
FDA analysis of industry-submitted
documents is ongoing. A new meeting
date will be announced in the Federal
Register.
FOR FURTHER INFORMATION CONTACT:
Jamie Waterhouse, Center for Devices
and Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 1611, Silver Spring,
MD 20993–0002,
Jamie.Waterhouse@fda.hhs.gov, 301–
796–3063, or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area). Please call the Information Line
for up-to-date information on this
meeting.
wreier-aviles on DSK5TPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
14:48 Apr 03, 2013
Jkt 229001
Food and Drug Administration,
HHS.
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Peripheral and
Central Nervous System Drugs Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on May 22, 2013, from 8 a.m. to 5
p.m.
Location: FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (rm.
1503), Silver Spring, MD 20993–0002.
Information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/default.htm; under
the heading ‘‘Resources for You,’’ click
on ‘‘Public Meetings at the FDA White
Oak Campus.’’ Please note that visitors
to the White Oak Campus must enter
through Building 1.
Contact Person: Glendolynn S.
Johnson, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, rm. 2417, Silver Spring,
MD 20993–0002, 301–796–9001, FAX:
301–847–8533, email:
PCNS@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
Agenda: On May 22, 2013, the
committee will discuss new drug
application (NDA) 204569, for
suvorexant tablets, submitted by Merck
Sharp and Dohme Corp., Worldwide
Regulatory Group. The proposed
indication is for insomnia characterized
by difficulties with sleep onset and/or
maintenance.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before May 8, 2013. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before April 30,
2013. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by May 1, 2013.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 78, Number 65 (Thursday, April 4, 2013)]
[Notices]
[Pages 20327-20328]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-07843]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0001]
Joint Meeting of the Advisory Committee for Reproductive Health
Drugs and the Drug Safety and Risk Management Advisory Committee;
Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing an amendment
to the notice of the joint meeting of the Advisory Committee for
Reproductive Health Drugs and the Drug Safety and Risk Management
Advisory Committee. This meeting was announced in the Federal Register
of March 14, 2013 (78 FR 16271-16272). The amendment is being made to
reflect a change in the Agenda portion of the document. There are no
other changes.
FOR FURTHER INFORMATION CONTACT: Kalyani Bhatt, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31 rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, FAX: 301-847-8533, ACRHD@fda.hhs.gov, or use the FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington DC area), and follow the prompts to the desired center or
product area. Please call the Information Line for up-to-date
information on this meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of March 14, 2013,
FDA announced that a joint meeting of the Advisory Committee for
Reproductive Health Drugs and the Drug Safety and Risk Management
Advisory Committee would be held on April 18, 2013. On page 16272, in
the first column, the Agenda portion of the document is changed to read
as follows:
Agenda: The committee will discuss the efficacy and safety of new
drug application (NDA) 22219, AVEED (testosterone undecanoate)
intramuscular injection, submitted by Endo Pharmaceutical Solutions,
Inc., for the proposed indication of replacement
[[Page 20328]]
therapy in adult males for conditions associated with a deficiency or
absence of testosterone. The safety discussion will focus on
postmarketing reports of oil microembolism in the lungs and potential
anaphylactic reactions. In addition to AVEED, other approved
testosterone injectable products will be referenced, especially in
regard to oil microembolism and potential anaphylactic reactions
reported for those products.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: March 27, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2013-07843 Filed 4-3-13; 8:45 am]
BILLING CODE 4160-01-P